Yes, Opana is a narcotic. It’s the brand name for oxymorphone, a Schedule II opioid analgesic. In clinical and regulatory contexts, “narcotic” and “opioid” often mean the same thing. Oxymorphone is a morphine analog with similar actions, but it’s several times more potent than morphine and oxycodone. That potency drives its high abuse and dependence potential. Understanding where it fits among opioids clarifies why medical supervision matters so much.
Key Takeaways
- “Narcotic” reflects legal and regulatory frameworks, while “opioid” describes mechanism; both terms apply interchangeably to oxymorphone.
- Oxymorphone is a morphine analog with similar actions but lacks morphine’s cough suppressant activity, and is metabolically linked to oxycodone.
- As a Schedule II controlled substance (ACSCN 9652), oxymorphone carries high abuse potential and severe physical and psychological dependence risks.
- Oxymorphone delivers substantially greater analgesic potency than morphine and oxycodone, ranking among the most potent Schedule II opioids.
Is Opana a narcotic
Yes, Opana is a narcotic. Opana is the brand name for oxymorphone, an opioid analgesic classified within the drug class of narcotic analgesics. In medical and regulatory contexts, the term “opioid” is often used interchangeably with “narcotic,” so both labels apply to what you’re taking.
Oxymorphone acts as an opioid agonist on your central nervous system to relieve pain. It’s a morphine analog with actions similar to morphine, though it lacks cough suppressant activity. You’d receive it for moderate to severe acute pain where opioid use is appropriate.
Because it’s a highly potent opioid, oxymorphone carries the pharmacological properties and risks characteristic of narcotics. This classification helps you recognize why Opana requires careful medical supervision during use.
What does narcotic actually mean
“Narcotic” is a word rooted in regulatory and legal frameworks, often signaling controlled-substance status. Two terms often blur together in clinical settings: “narcotic” and “opioid.” In medical and regulatory contexts, they’re frequently used interchangeably, and that’s why your Opana falls under both labels. “Opioid,” by contrast, describes the pharmacological mechanism: a drug acting as an agonist on central nervous system receptors to relieve pain. Oxymorphone fits both descriptions precisely. It’s an opioid analgesic within the narcotic analgesic class, functioning as a morphine analog with actions similar to morphine. Opana was a brand name for oxymorphone, a Schedule II opioid analgesic. Although the Opana and Opana ER brands are discontinued in the United States, FDA-approved oxymorphone products may still be available in generic form.
Where oxymorphone fits in the opioid family
Oxymorphone sits firmly within the opioid family, closely tied to both morphine’s structure and oxycodone’s metabolism as a potent, tightly controlled analgesic. Oxymorphone is a morphine analog, sharing similar actions but lacking the cough suppressant activity you’d find in morphine itself. It works as an opioid agonist on your central nervous system to relieve pain. You’ll find it ranks among the highly potent opioids, with an abuse liability comparable to morphine and other Schedule II agents. There’s also a direct metabolic connection: when you take oxycodone, your body converts it into oxymorphone, which explains their comparable abuse potential. Oxymorphone relates to morphine, the reference compound against which most opioids are measured.
What schedule is oxymorphone (Schedule II) and why
Oxymorphone is a Schedule II controlled substance under the US Controlled Substances Act, a classification the DEA assigns to substances with high abuse potential and a recognized medical use. You’ll find it identified by the Administrative Controlled Substances Code Number (ACSCN) 9652. This scheduling reflects oxymorphone’s capacity to produce severe physical and psychological dependence, comparable to morphine and other Schedule II opioids. Because oxycodone metabolizes into oxymorphone, the two share a similar abuse liability profile. The drug’s high potency compounds these risks, making misuse and diversion significant concerns. In fact, on June 8, 2017, In June 2017, the FDA requested the removal of reformulated Opana ER, an extended-release oral tablet, after determining that the risks associated with its abuse outweighed its benefits. Oxymorphone is a substance whose therapeutic value and abuse potential both demand strict regulatory control.
How its potency compares to morphine and oxycodone
Oxymorphone delivers substantially greater analgesic potency than both morphine and oxycodone. As a morphine analog, it shares many of morphine’s actions but ranks among the most potent Schedule II agents. It works as an opioid agonist on your central nervous system to relieve moderate to severe pain, but it lacks morphine’s cough suppressant activity.
| Opioid | Relationship to Oxymorphone |
|---|---|
| Morphine | Parent compound; oxymorphone is a more potent analog |
| Oxycodone | Metabolizes into oxymorphone in your body |
| Oxymorphone | Highly potent; comparable abuse liability to morphine |
| Abuse Potential | Similar across all three Schedule II agents |
| Analgesia | Oxymorphone exceeds morphine’s potency |
Understanding these differences helps you recognize why careful dosing matters when you’re managing severe pain.
Why its classification reflects a high abuse potential
Oxymorphone’s classification reflects a high abuse potential because the drug can produce severe physical and psychological dependence. The DEA classifies it as a Schedule II controlled substance under the Controlled Substances Act, assigning it the ACSCN 9652. You’ll find its abuse liability comparable to morphine and other Schedule II opioids. Significantly, oxymorphone’s abuse potential parallels oxycodone, which metabolizes into oxymorphone within the body. The drug’s high potency amplifies these risks, driving misuse. In fact, the FDA requested removal of the injectable reformulation on June 8, 2017, citing significant misuse risks. Oxymorphone’s pharmacological profile means its Schedule II status isn’t arbitrary. It directly corresponds to documented dependence liability and the serious consequences that accompany diversion and non-medical use.
How Miami Outpatient Detox connects people to opioid treatment
Miami Outpatient Detox connects you to medically supervised treatment that addresses the drug’s documented dependence liability when you’re dependent on oxymorphone or another Schedule II opioid. Because oxymorphone carries high abuse potential and produces both physical and psychological dependence, you need clinical oversight during withdrawal, not self-directed tapering. The program monitors respiratory depression risk, which peaks within the first 24, 72 hours of therapy and remains dangerous during detoxification.
You’ll receive evidence-based interventions calibrated to your dependence severity, whether you’ve used immediate-release tablets or extended-release Opana ER. Because oxymorphone shares abuse liability with morphine and oxycodone, your treatment plan reflects established protocols for Schedule II opioid dependence. You’ll proceed safely, with medical staff managing symptoms and reducing the fatal risks associated with unsupervised discontinuation or relapse.
Get Help for Oxymorphone Dependence in Miami
If oxymorphone use has led to dependence, withdrawal symptoms, or difficulty controlling your use, professional support can help you move forward safely. Miami Outpatient Detox can help you explore opioid detox, alcohol detox, medical detox, outpatient detox, and ongoing addiction treatment based on your clinical needs. Verify your insurance to review potential coverage, or call +1 (786) 228-8884 to discuss available treatment options in Miami.
Frequently Asked Questions
How Long Does Oxymorphone Stay in Your System?
Oxymorphone’s clearance depends on the formulation you’re taking. Immediate-release tablets deliver pain relief for 3, 4 hours, while extended-release formulations like Opana ER provide analgesia over 12 hours. The drug’s effects and detectability vary based on your metabolism, liver function, and dose. If you’ve got hepatic impairment, you’ll clear it more slowly. Always consult your prescriber, since factors like age, kidney function, and concurrent medications influence how long it stays active.
Can You Take Opana While Pregnant or Breastfeeding?
You shouldn’t take Opana while pregnant or breastfeeding unless your doctor determines it’s absolutely necessary. As a Schedule II opioid, oxymorphone crosses the placenta and can cause neonatal opioid withdrawal, respiratory depression, and other serious risks to your baby. It’s also excreted in breast milk, potentially causing drowsiness or breathing problems in nursing infants. Always discuss safer alternatives with your healthcare provider before using this potent narcotic during pregnancy or lactation.
What Are Common Withdrawal Symptoms From Stopping Oxymorphone?
If you stop oxymorphone suddenly after prolonged use, you’ll likely experience withdrawal symptoms tied to physical dependence. You may notice anxiety, restlessness, sweating, and muscle aches. You could also develop nausea, vomiting, diarrhea, abdominal cramps, and dilated pupils. Watch for insomnia, chills, yawning, a runny nose, and rapid heartbeat too. Because oxymorphone’s a potent Schedule II opioid, you shouldn’t quit abruptly talk with your prescriber about gradually tapering your dose to minimize these effects.
Does Insurance Typically Cover Opana or Its Alternatives?
Insurance coverage varies by your specific plan, so you’ll need to verify directly with your provider. The knowledge provided doesn’t include insurance or cost information, so I can’t give you specifics. Generally, you’d check your plan’s formulary to confirm whether Opana (oxymorphone) or its alternatives are covered, and whether prior authorization applies. Since coverage differs widely, contact your insurer or pharmacist for accurate details about your out-of-pocket costs.
Are There Generic Versions of Opana Still Available?
Yes, you’ll find generic oxymorphone still available in immediate-release tablet form for moderate to severe acute pain. However, you should know the extended-release version (Opana ER) was withdrawn from the market in 2017 after the FDA requested removal due to serious misuse and abuse risks. If you’re prescribed generic oxymorphone, you’ll typically access the immediate-release formulation, which you take every 4, 6 hours as needed for pain relief.